颌下腺移植与小涎腺移植治疗干眼的比较:一项回顾性队列研究
本回顾性队列研究纳入73只难治性干眼眼,比较颌下腺移植(A组35只终末期眼)与小涎腺移植(B组20只终末期眼、C组18只非终末期眼)的疗效。A组术后2年以上随访中Schirmer试验、泪膜破裂时间、角膜荧光素染色和最佳矫正视力均显著改善;B组仅Schirmer试验和角膜荧光素染色有限改善;C组除最佳矫正视力外均显著改善。结论认为终末期难治性干眼可推荐颌下腺移植,而小涎腺移植可能对眼部损害相对较轻的难治性干眼提供满意结果。
要点
- A组终末期干眼行颌下腺移植,术后2年以上Schirmer试验等四项指标均显著改善。
- B组终末期干眼行小涎腺移植,仅Schirmer试验和角膜荧光素染色有限改善。
- C组非终末期干眼行小涎腺移植,除最佳矫正视力外其余指标显著改善。
核心结论
- 作者认为终末期难治性干眼可推荐颌下腺移植。
- 作者认为小涎腺移植可能对眼部损害相对较轻的难治性干眼提供满意结果。
研究设计与样本
- 回顾性临床队列研究,共纳入73只难治性干眼眼,分为3组。
- A组35只终末期干眼眼行颌下腺移植,B组20只终末期干眼眼行小涎腺移植,C组18只非终末期干眼眼行小涎腺移植。
- 术前及术后测量Schirmer试验、泪膜破裂时间、角膜荧光素染色和最佳矫正视力。
主要发现
- A组住院时长、手术时长和住院费用显著高于B组或C组。
- A组术前Schirmer试验0.36 mm/5分钟、泪膜破裂时间0.03秒、角膜荧光素染色10.97、最佳矫正视力0.11,术后2年以上随访分别显著改善至20.23 mm/5分钟、1.74秒、7.58、0.2。
- B组基线数据与A组相似,术后仅Schirmer试验(0.55 mm/5分钟至3.79 mm/5分钟)和角膜荧光素染色(11.10至9.58)有显著但有限的改善。
- C组基线Schirmer试验0.89 mm/5分钟、泪膜破裂时间3.49秒、角膜荧光素染色1.83、最佳矫正视力0.81,小涎腺移植术后分别显著改善(最佳矫正视力除外)至9.35 mm/5分钟、9.08秒、0.53、0.89。
临床怎么用
- 作者认为终末期难治性干眼可推荐颌下腺移植。
- 作者认为小涎腺移植可能对眼部损害相对较轻的难治性干眼提供满意结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare submandibular gland (SMG) transplantation with minor salivary gland (MSG) transplantation for the treatment of different dry eye diseases (DED). DESIGN: Retrospective clinical cohort study. METHODS: A total of 73 refractory DED eyes were divided into 3 groups. Group A comprised 35 end-stage DED eyes that underwent SMG transplantation. Group B comprised 20 end-stage DED eyes with MSG transplantation. Group C comprised 18 non-end-stage DED eyes with MSG transplantation. Schirmer test (ST), tear break-up time (TBUT), corneal fluorescein staining (FL), and best-corrected visual acuity (BCVA) were measured before and after surgery. RESULTS: Hospital length of stay, length of operation, and hospital fee were significantly higher in group A than in group B or C. Eyes in group A showed the most severe DED disease, with preoperative ST, TBUT, FL, and BCVA of 0.36 mm per 5 minutes, 0.03 seconds, 10.97, and 0.11, respectively, which improved significantly to 20.23 mm per 5minutes, 1.74 seconds, 7.58, and 0.2 at >2-year follow-up. Group B had similar baseline data, and significant but limited improvement only in the ST (0.55 mm per 5 minutes to 3.79 mm per 5 minutes) and FL (11.10 to 9.58) after the operation. Group C had better baseline ST, TBUT, FL, and BCVA of 0.89 mm per 5min, 3.49 seconds, 1.83, and 0.81, respectively, which improved significantly (except for BCVA) to 9.35 mm per 5min, 9.08 s, 0.53, and 0.89 after MSG transplantation. CONCLUSION: SMG transplantation could be recommended to treat end-stage refractory DED. MSG transplantation may provide satisfying results for refractory DED with relatively less severe impairment of the eye.
引用
- Su JZ, Zheng B, Wang Z, et al. Submandibular Gland Transplantation vs Minor Salivary Glands Transplantation for Treatment of Dry Eye: A Retrospective Cohort Study. Am J Ophthalmol. 2022. PMID: 35640736. doi:10.1016/j.ajo.2022.05.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。